Search

Your search keyword '"Di Battista, Marco"' showing total 8 results
Start Over Author "Di Battista, Marco" Publication Year Range This year
8 results on '"Di Battista, Marco"'

1. Contributors

Author

Abu-Shakra, Mahmoud, primary, Adiguzel, Yekbun, additional, Al Shawaf, Maisam, additional, Alghory, Amal, additional, Almeida, Isabel, additional, Alrais, Mahmoud, additional, Alrifaai, Mohamad Aosama, additional, Alwani, Abdulkarim, additional, Alwani, Abdulrahman, additional, Amital, Howard, additional, Anna, Dubaniewicz, additional, Arleevskaya, Marina, additional, Ashkenazi, Shai, additional, Athanassiou, Lambros, additional, Athanassiou, Panagiotis, additional, Atik, Houda, additional, Atzeni, Fabiola, additional, Balbir-Gurman, Alexandra, additional, Balcioglu, Zeynep Betul, additional, Baldini, Chiara, additional, Barbour, Mohammad, additional, Bashi, Tomer, additional, Belyaeva, Irina V., additional, Ben-Ami, Dana, additional, Blank, Miri, additional, Boccassini, Laura, additional, Bogdanos, Dimitrios P., additional, Bombardieri, Stefano, additional, Bost, Chloé, additional, Brandão, Mariana, additional, Braun-Moscovici, Yolanda, additional, Brooks, Wesley H., additional, Campar, A., additional, Carvalheiras, Graziela, additional, Cervera, R., additional, Churilov, Leonid P., additional, Cohen, Eytan, additional, Correia, J., additional, Darkhabani, Mohammad, additional, David, Paula, additional, de Carvalho, Jozélio Freire, additional, Deniz, Omer Faruk, additional, Detrick, Barbara, additional, Deutsch, Melanie, additional, Di Battista, Marco, additional, Dogan, Emir, additional, Dogru, Omer Faruk, additional, Domingues, Vital Da Silva, additional, Dotan, Arad, additional, Dow, Coad Thomas, additional, Durai, Malarvizhi, additional, Elefante, Elena, additional, Elsalti, Abdulrahman, additional, Erman, Mikhail V., additional, Esirgun, Sevval Nil, additional, Ferrão, C., additional, Ferreira, Álvaro, additional, Ferro, Francesco, additional, Fonseca, Tomás, additional, Garg, Ravindra Kumar, additional, Guilherme, Luiza, additional, Habra, Mona, additional, Halpert, Gilad, additional, Hammerstad, Sara Salehi, additional, Hooks, John J., additional, Ilchovska, Daisy, additional, Invernizzi, Pietro, additional, Israeli, E., additional, Janket, Sok-Ja, additional, Kalil, Jorge, additional, Karaoglan, Birnur Sinem, additional, Kiyak, Zeynep, additional, Kol, Mustafa Yusuf, additional, Kostoglou-Athanassiou, Ifigenia, additional, Krause, Ilan, additional, Kudryavtsev, Igor V., additional, Kumar, Neeraj, additional, Lavine, Noy, additional, Lerman, Tsahi T., additional, Levi, Assi, additional, Ling, Eduard, additional, Moutsopoulos, Haralampos M., additional, Mahajna, Hussein, additional, Mahroum, Naim, additional, Malhotra, Hardeep Singh, additional, Malkova, Аnna M., additional, Maoz-Segal, Ramit, additional, Marinho, António, additional, Mavragani, Clio P., additional, Meurman, Jukka H., additional, Milhes, Jean, additional, Mimouni, Daniel, additional, Morais, Cátia Iracema, additional, Moudgil, Kamal D., additional, Muniz Caldas, Cezar Augusto, additional, Neves, Esmeralda, additional, Neyestani, Kamyar, additional, Nikolaev, Alexei V., additional, Noversa de Sousa, Rita, additional, Ohayon, Aviran, additional, Palumbo, Antonino, additional, Pasoto, Sandra Gofinet, additional, Petríková, Jana, additional, Puxeddu, Ilaria, additional, Raftopoulou, Sylvia, additional, Renaudineau, Yves, additional, Ribeiro, Francinne Machado, additional, Rigopoulou, Eirini I., additional, Rosário, Cristina, additional, Rossa, Alessandra Della, additional, Sahin, Meyha, additional, Sarzi-Puttini, Piercarlo, additional, Seguro, Luciana Parente Costa, additional, Seida, Isa, additional, Seida, Ravend, additional, Serpa Pinto, L., additional, Sharon, Eran, additional, Shoenfeld, Yehuda, additional, Smyk, Daniel S., additional, Sousa, Rita Catarina Medeiros, additional, Starshinova, Anna A., additional, Tamimi, Faleh, additional, Tocut, Milena, additional, Tomer, Yaron, additional, Tunitsky-Lifshitz, Yulia, additional, Vasconcelos, Carlos, additional, Vasconcelos, Júlia, additional, Vassilopoulos, Dimitrios, additional, Venkatesha, Shivaprasad H., additional, Villanueva, Ronald, additional, Vita, Pedro, additional, Yablonskiy, Piotr K., additional, Yilmaz, Mesut, additional, Zamorano, Bryan, additional, Zandman-Goddard, Gisele, additional, Zinchenko, Yulia S., additional, and Zoubi, Magdi, additional

Published
2024
Full Text
View/download PDF

6. Lung ultrasound and high-resolution computed tomography quantitative variations during nintedanib treatment for systemic sclerosis-associated interstitial lung disease.

Author

Di Battista M, Delle Sedie A, Romei C, Tavanti L, Da Rio M, Morganti R, Della Rossa A, and Mosca M

Subjects
Humans, Female, Male, Middle Aged, Aged, Respiratory Function Tests, Patient Reported Outcome Measures, Quality of Life, Treatment Outcome, Scleroderma, Systemic complications, Scleroderma, Systemic drug therapy, Scleroderma, Systemic diagnostic imaging, Lung Diseases, Interstitial drug therapy, Lung Diseases, Interstitial diagnostic imaging, Lung Diseases, Interstitial etiology, Indoles therapeutic use, Tomography, X-Ray Computed methods, Ultrasonography, Lung diagnostic imaging, Lung physiopathology
Abstract

Objectives: Lung ultrasound (LUS) and high-resolution CT (HRCT) are commonly used for the evaluation of interstitial lung disease (ILD). Nintedanib (NIN) is an antifibrotic therapy approved for systemic sclerosis-associated ILD (SSc-ILD). We assessed LUS and quantitative HRCT changes in SSc-ILD patients treated with NIN during a 1 year follow-up, evaluating relationships between imaging variations and functional or quality-of-life outcomes., Methods: SSc-ILD patients who started NIN were enrolled and followed for 12 months. Pulmonary function tests and patient-reported outcome measures (PROMs) were assessed half-yearly and quarterly, respectively. LUS was performed quarterly evaluating the presence of B-lines (BL) and pleural line irregularities (PLI). HRCT was repeated after 1 year and quantitatively analysed with CALIPER software., Results: Ten patients (70% female, mean age 62 years) were enrolled. The mean total number of both BL and PLI was constantly decreased during NIN treatment, being significantly reduced after 12 months (from 175.1 [66.7] to 120.8 [70.3] for BL, P = 0.005; and from 50.6 [32.5] to 37.2 [22.4] for PLI, P = 0.05). Male gender, smoking habit and baseline forced vital capacity <70% predicted were associated with worse LUS outcomes. A greater reduction in both BL and PLI was observed in those who improved in PROMs, especially modified Medical Research Council dyspnoea scale (P = 0.016 and P = 0.04, respectively) and Saint George's Respiratory Questionnaire (P = 0.006 and P = 0.026, respectively). No significant changes in the CALIPER percentages of normal parenchyma or ILD elements were observed after 12 months of NIN, thus paralleling the stabilization obtained at pulmonary function tests., Conclusion: We present preliminary results on NIN effects on SSc-ILD as assessed by LUS, a useful method for frequently repeated monitoring, and CALIPER, a valid implementation whenever a HRCT is performed., (© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2024
Full Text
View/download PDF

7. Efficacy of intravenous immunoglobulins in severe scleromyxedema dysphagia assessed by oesophageal scintigraphy.

Author

Di Battista M, Grosso M, Marciano A, Scarpuzza M, Della Rossa A, and Mosca M

Subjects
Humans, Treatment Outcome, Female, Middle Aged, Radionuclide Imaging, Esophagus diagnostic imaging, Esophagus pathology, Male, Severity of Illness Index, Predictive Value of Tests, Adult, Immunoglobulins, Intravenous administration & dosage, Immunoglobulins, Intravenous therapeutic use, Deglutition Disorders etiology, Deglutition Disorders diagnostic imaging, Deglutition Disorders drug therapy, Scleromyxedema complications, Scleromyxedema drug therapy, Scleromyxedema diagnostic imaging
Published
2024
Full Text
View/download PDF

8. Systemic sclerosis: one year in review 2024.

Author

Lepri G, Di Battista M, Codullo V, Bonomi F, Sulis A, Guiducci S, and Della Rossa A

Subjects
Humans, Prognosis, Risk Factors, Scleroderma, Systemic immunology, Scleroderma, Systemic therapy, Scleroderma, Systemic diagnosis
Abstract

Systemic sclerosis (SSc) is a rare and chronic connective tissue disease of unknown aetiology and characterised by three main pathogenetic events represented by endothelial damage, inflammation with activation of the immune system leading to production of specific autoantibodies and finally fibrosis. SSc is a heterogeneous disease and the classification in two subsets, the limited cutaneous (lcSSc) subset and the diffuse cutaneous one (dcSSc), is not capable of capturing the broad and different phenotypic expression of the disease. In the last years progress has been made in the knowledge of SSc pathogenesis, in its early diagnosis and new therapeutic strategies have been proposed, however, the management of SSc still represents a challenge for the clinician. For this reason, every year several studies investigate new insights of disease pathogenesis, internal organ involvement and therapeutic approaches. The purpose of this review is to provide an overview of the literature published in 2023.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results